Summary, slides, & video from the CARB-X + GARDP Bootcamps, 5-8 Sep 2017 ASM-ESCMID Conference

This note was updated on 12 Jan 2018 to provide links to the videos from the bootcamp sessions.

Dear All: 

GARDP + CARB-X have this week hosted Antibiotic Bootcamps #1, #2, and #3 at the ASM-ESCMID conference on antibiotic R&D. There were nearly 350 people registered for the full meeting with good attendance at each Bootcamp. 

Bootcamp #1 (Lynn Silver, Tom Dougherty, Sherman Waddell, and John Tomayko) covered the question of finding interesting start points for R&D: What makes a good hit? What makes a good lead? Who were Lipinski and Oprea and why should you care? Watch the video.

Bootcamp #2 (Tim Keutzer, Evan Hecker, and Mike Young, and Andrew Barlow) took us through the challenges of CMC (Chemistry, Manufacturing, and Controls). Building on the hypothetical case of drug X-1 used for last year’s FDA workshop on developing narrow-spectrum antibiotics, the speakers showed clearly how CMC considerations must be front and center from a very early stage in any development program. Watch the video.

Bootcamp #3 (Erika Matuschek, Kevin Krause, Robin Patel, and Judith Steenbergen) took us through the mysteries of susceptibility testing. It was a soup-to-nuts review that should be reviewed along with the materials from the 13 Sep 2017 FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance. Watch the video.

The speakers have also agreed to share their slides.This .zip file (4.4MB) contains the talks from Bootcamps #1 and #2 (note that Bootcamp #2 is provided as a single presentation). And, here is the .zip file (2.3 MB) for the slides from Bootcamp #3. See links after my signature to the individual files.

Again, many thanks to the speakers and to ASM-ESCMID for enabling GARDP & CARB-X to host these events!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Note: If you have trouble unzipping the .zip files, here are links to the individual files provided by the speakers:

Upcoming meetings of interest to the AMR community:

  • 18 Jan 2018 (Geneva): Release of the First Annual Progress Report in support of the UN Sustainable Development Goals (SDG 3 in particular) by the AMR Industry Alliance
  • 12-14 Feb 2018 (Baltimore): ASM Biothreats Conference
  • 28 Feb 2018 (Brussels): Deadline for responses to IMI2 Call 13 (Topic 3) on AMR diagnostics
  • 11-16 Mar 2018 (Ventura Beach): Gordon Research Conference on Antibacterial Discovery
  • 21-24 Apr 2018 (Madrid): ECCMID
  • [NEW] 4-7 Jun 2018 (Boston): BIO (multiple AMR-focused sessions are expected)
  • 7-11 Jun 2018 (Atlanta): ASM Microbe
  • 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
  • [Don’t miss this one] 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal) (initial flyer)
  • 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France) (link to 2017 program — details pending for 2018)

Share

Path to UNGA 2024 as of 3 May 24 / Events on 14-15 May (DC, NYC)

Dear All, Well, ECCMID 2024 (Barcelona) has come and gone. I saw many of you there … but it’s always so busy … and the conference center was simply enormous! Could not keep up. But, it was great to get the sense that we’re back as a community … very good attendance. The one thing

R&D Implications: Global Burden Disease is 28% Infectious!

Dear All (with thanks to Erin Duffy for co-authoring and with a wonkish alert! Refresh your coffee!), In a fascinating follow-up to their 2022 paper on the global burden of antimicrobial resistance (20 Jan 2022 newsletter entitled “#AMRSOS! GRAM Report: ‘At Least 1.27m Deaths/Year Directly Attributable To AMR’”), the team at IHME (Institute for Health

OHE £40k Policy Innovation Prize: AMR, anyone?

Dear All, One of your alert co-readers (Abigail Herron) pointed out to me the currently open call for applications for the OHE (Office of Health Economics) Innovation Policy Prize, a biennial £40k prize seeking “to promote thought leadership and solution-based theories around the big questions affecting the future of our industry.” Intriguingly for the AMR community, their

WHO call for data on pre-clinical antifungal R&D projects

Dear All, As part of their long-running project to maintain a useful view of the global antibacterial and antifungal pipelines, WHO yesterday announced a call for data on pre-clinical antifungal R&D projects. The scope is anything from Lead Optimization to pre-IND. Here are the links you need: The WHO webpage describing the call for data

Scroll to Top